Insmed Incorporated is expected to post earnings of ($ 0.71) per share in the first quarter of 2022 (NASDAQ: INSM)

Insmed Incorporated (NASDAQ: INSM) – SVB Leerink investment analysts released their first quarter 2022 EPS estimates for Insmed in a research report released to clients and investors on Friday, August 6. SVB Leerink analyst J. Schwartz expects the biopharmaceutical company to post earnings per share of ($ 0.71) for the quarter. SVB Leerink also released estimates for Insmed Q2 2022 earnings at ($ 0.72) EPS, Q3 2022 earnings at ($ 0.74) EPS, and Q4 2022 earnings at ($ 0.75 EPS ). Insmed (NASDAQ: INSM) last released its quarterly results on Thursday, August 5. The biopharmaceutical company reported ($ 1.07) earnings per share for the quarter, missing the consensus estimate of ($ 0.89) of ($ 0.18). The company posted revenue of $ 45.37 million in the quarter, compared to analysts’ estimates of $ 43.72 million. Insmed recorded a negative return on equity of 103.03% and a negative net margin of 190.36%. Insmed’s turnover is up 6.8% compared to the same quarter last year. During the same period of the previous year, the company posted EPS ($ 0.64).

Several other equity research analysts have also weighed on the company recently. Morgan Stanley lowered its price target on Insmed from $ 58.00 to $ 56.00 and set an “overweight” rating for the company in a report released on Monday, May 10. Zacks Investment Research downgraded Insmed’s stock from a “hold” rating to a “buy” rating and set a price target of $ 31.00 for the company in a report released Thursday, July 8. Seven research analysts rated the stock with a buy rating. The stock currently has an average rating of “Buy” and a consensus target price of $ 50.57.

NASDAQ INSM shares opened at $ 25.60 on Monday. The company has a debt ratio of 1.86, a quick ratio of 5.52, and a current ratio of 6.16. The company has a market cap of $ 2.65 billion, a P / E ratio of -8.10 and a beta of 2.23. The company has a 50-day simple moving average of $ 27.02. Insmed has a minimum of $ 23.16 over 52 weeks and a maximum of $ 45.44 over 52 weeks.

(A d)

I believe we are on the cusp of something we haven’t seen in 20 years. Fortunes will be made and lost.

Several hedge funds have recently increased or reduced their stakes in the company. Virtus ETF Advisers LLC increased its stake in Insmed shares by 2.8% in the 1st quarter. Virtus ETF Advisers LLC now owns 15,678 shares of the biopharmaceutical company valued at $ 534,000 after acquiring 426 additional shares in the last quarter. Eaton Vance Management acquired a new position in Insmed shares in Q1 valued at approximately $ 36,000. Calton & Associates Inc. increased its equity stake in Insmed by 21.9% in the 1st quarter. Calton & Associates Inc. now owns 8,988 shares of the biopharmaceutical company valued at $ 306,000 after purchasing an additional 1,613 shares during the period. Teacher Retirement System of Texas increased its stake in Insmed shares by 17.5% in the 2nd quarter. Teacher Retirement System of Texas now owns 13,374 shares of the biopharmaceutical company valued at $ 381,000 after purchasing an additional 1,995 shares during the period. Finally, Harbor Investment Advisory LLC acquired a new position in Insmed shares in the second quarter valued at approximately $ 58,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company with a mission to transform the lives of patients with severe and rare diseases. Insmed’s first commercial product is ARIKAYCE® (Amikacin Liposome Inhalation Suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a regimen Combined antibacterial for adult patients with little or no alternative treatment option.

Further Reading: Trading Signals Using Bollinger Bands

Insmed revenue history and estimates (NASDAQ: INSM)

This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Insmed now?

Before you consider Insmed, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and Insmed was not on the list.

Although Insmed currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

Source link

Comments are closed.